KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sarepta Therapeutics (SRPT) Cash from Financing Activities (2016 - 2025)

Sarepta Therapeutics (SRPT) has 15 years of Cash from Financing Activities data on record, last reported at -$39.2 million in Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 180.03% year-over-year to -$39.2 million; the TTM value through Dec 2025 reached -$168.3 million, down 234.88%, while the annual FY2025 figure was -$168.3 million, 234.88% down from the prior year.
  • Cash from Financing Activities reached -$39.2 million in Q4 2025 per SRPT's latest filing, up from -$117.8 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $549.2 million in Q4 2021 and bottomed at -$117.8 million in Q3 2025.
  • Average Cash from Financing Activities over 5 years is $43.8 million, with a median of $8.3 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: skyrocketed 3567.05% in 2022, then crashed 956.22% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $549.2 million in 2021, then tumbled by 98.04% to $10.7 million in 2022, then plummeted by 81.92% to $1.9 million in 2023, then soared by 2421.41% to $49.0 million in 2024, then tumbled by 180.03% to -$39.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were -$39.2 million in Q4 2025, -$117.8 million in Q3 2025, and -$23.8 million in Q2 2025.